Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

10x Genomics (TXG) stock in plain English

Free brief · no signupStart here
TXGPublished Nov 18, 2026
10x Genomics Inc
Healthcare · Medical Devices
Manufactures instruments, microfluidic chips, and chemical reagents for single-cell genetic sequencing.
Assets:
Chromium platformAutomated instruments and microfluidic chips for high-throughput single-cell barcoding.
Xenium and VisiumIn situ imaging systems that map gene expression across intact tissue slices.
Pleasanton campusHouses primary manufacturing facilities, research laboratories, and headquarters in California.
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

67
OPS ScoreOperating finances
Latest quote
+0.54%$57.38
$7.55B
n/a (loss)
$618.64M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 18, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was TXG. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does 10x Genomics (TXG) do?

10x Genomics Inc (TXG) is a U.S.-listed company in Healthcare (Medical Devices). What it does: Manufactures instruments, microfluidic chips, and chemical reagents for single-cell genetic sequencing. Builds integrated hardware, reagents, and software that analyze genetic activity inside individual biological cells. It is worth $7.55B on the market and sold $618.64M over the last year.

Market cap
$7.55B
P/E ratio
None (reported a loss)
Annual sales
$618.64M
Sector
Healthcare
Industry
Medical Devices
Brief updated
Nov 18, 2026

Brands and businesses behind TXG

  • Chromium: Hardware instruments and reagent kits that isolate single cells for RNA sequencing assays.
  • Visium: Spatial transcriptomics kits that map gene expression onto intact tissue histology slides.
  • Xenium: In situ optical instruments that measure targeted RNA and protein molecules inside subcellular tissue compartments.

TXG’s flags, in plain English

Each flag is a number from 10x Genomics’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 18, 2026.

Stupid Cash

Can pay this year's bills 5.1 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Low debt

Low debt, only 9% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Wide Gross Margin

Gross margin of 72.5% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Burning Cash

Losing money, profit margin of -10.8%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.

2 more green flags and 1 more risk note open with the free trial. Try it free for 7 days.

Questions about TXG

How big is 10x Genomics?

10x Genomics’ market cap is $7.55B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $618.64M: what customers paid the company over the last year, before any costs.

What is TXG’s P/E ratio?

TXG has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with TXG?

The business depends heavily on capital spending and grants from academic institutions, which fluctuate with government funding. That is one risk on 10x Genomics’ card. Its first risk flag is Burning Cash, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From 10x Genomics’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. TXG’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card